Lerner, A Martin, Beqaj, Safedin H, Deeter, Robert G et al. · In vivo (Athens, Greece) · 2002
Researchers tested blood samples from ME/CFS patients and healthy controls for specific antibodies to cytomegalovirus (CMV), a common virus. They found that 16 ME/CFS patients had unique antibodies to two CMV proteins (p52 and CM2) that were not found in 77 control subjects, including other ME/CFS patients and healthy people. This suggests these antibodies might be a specific marker for a subset of ME/CFS patients and could indicate an ongoing or incomplete CMV infection in this group.
If confirmed, this finding could provide the first specific laboratory test to identify a biological subgroup of ME/CFS patients with active or persistent CMV infection, potentially enabling targeted antiviral interventions and improving diagnostic accuracy. This work supports the hypothesis that viral reactivation may contribute to ME/CFS pathogenesis in some patients.
This small, early-stage study does not prove that CMV causes ME/CFS or that treating CMV will cure the disease; the presence of specific antibodies indicates infection exposure but does not establish causality. The study is cross-sectional and cannot determine whether CMV reactivation precedes or results from ME/CFS. Replication in larger, prospective cohorts is essential before clinical application.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Lerner, A Martin, Beqaj, Safedin H, Deeter, Robert G, & Fitzgerald, James T (2002). IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome.. In vivo (Athens, Greece). https://pubmed.ncbi.nlm.nih.gov/12182109/
BibTeX
@article{mecfsatlas-lerner-2002-igm-serum,
author = {Lerner, A Martin and Beqaj, Safedin H and Deeter, Robert G and Fitzgerald, James T},
title = {IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome.},
journal = {In vivo (Athens, Greece)},
year = {2002},
note = {PubMed: 12182109},
url = {https://www.mecfsatlas.com/evidence/lerner-2002-igm-serum},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-30. https://www.mecfsatlas.com/evidence/lerner-2002-igm-serum
Contribute
Private, reviewed by a human. Not a public comment thread.